Edwards Lifesciences Cash Flow Statement
EW / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Edwards Lifesciences generated $1.6B in operating cash flow and $1.3B in free cash flow in FY2025. Free cash flow margin was 22.0% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.1B | $4.2B | $1.5B | $1.5B | $1.5B | - | - | - | - | - | - | - | - | - | - |
| Depreciation & Amortization | $156.6M | $155.2M | $134.8M | $139.6M | $134.8M | $107.2M | $89.3M | $77.4M | $81.9M | $71.2M | $65.8M | $68.6M | $62.9M | $53.7M | $58.0M |
| Operating Cash Flow | $1.6B | $542.3M | $1.7B | $1.2B | $1.7B | $1.1B | $1.2B | $926.7M | $1.0B | $704.4M | $549.7M | $1.0B | $472.7M | $362.1M | $308.2M |
| Capital Expenditures | $260.2M | $252.4M | $325.8M | $244.6M | $325.8M | $407.0M | $254.4M | $238.7M | $168.1M | $176.1M | $102.7M | $82.9M | $109.0M | $109.0M | $76.6M |
| Free Cash Flow | $1.3B | $289.9M | $1.4B | $973.6M | $1.4B | $647.3M | $928.5M | $688.0M | $832.6M | $528.3M | $447.0M | $939.4M | $363.7M | $253.1M | $231.6M |
| Share Buybacks | $893.4M | $1.2B | $512.8M | $1.7B | $512.8M | $625.4M | $263.3M | $795.5M | $763.3M | $662.3M | $280.1M | $300.9M | $496.9M | $344.1M | $303.4M |
| FCF Margin | 22.0% | 5.3% | 26.9% | 21.8% | 26.9% | 14.8% | 21.3% | 18.5% | 24.2% | 17.8% | 17.9% | 40.4% | 17.8% | 13.3% | 13.8% |